Clinical trials: Multiple Cancers, open to volunteers
Breast Carcinoma, Cervical Carcinoma
The Ohio State University (OSU) SCREEN Community Program
This clinical trial develops and tests how well a multi-level intervention (MLI), The Ohio State University (OSU) SCREEN Community Program, works to increase screening and follow-up for breast, cervical and colorectal (CRC)…
- Conditions
- Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma
- Trial name
- NCT06666192
- Testing
- Cancer Screening, Discussion, Educational Activity
- Where
- United States
- Volunteers
- 2,067 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Rectal Cancer, Advanced Stage Colorectal Cancer
SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC
This is a multicenter, cohort, prospective study to evaluate the efficacy and safety of Adebrelimab combined with radiotherapy and chemotherapy as preoperative neoadjuvant therapy for patients with locally advanced rectal cancer.
- Conditions
- Rectal Cancer, Advanced Stage Colorectal Cancer, Radiotherapy
- Trial name
- NCT07284992
- Testing
- short-term radiotherapy combined with Adebrelimab and capox, long-term radiotherapy combined with Adebrelimab and capox
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Shandong Provincial Hospital
Head and Neck Carcinoma, Adenoid Cystic Carcinoma
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non…
- Conditions
- Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT03556228
- Testing
- VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 242 people
- Sponsor
- VM Oncology, LLC
Relapsed or Refractory Multiple Myeloma
A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
The purpose of this study is to characterize the safety of QLS4131 injection and to determine the recommended Phase 2 dose (RP2D) and to further evaluate the efficacy and safety of QLS4131 injection in participants with relapsed…
- Trial name
- NCT06500507
- Testing
- QLS4131 Injection
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with…
- Trial name
- MOMENTUM (NCT07284758)
- Testing
- Cemsidomide, Dexamethasone
- Where
- 60 sites in United States, France and 4 more
- Volunteers
- 100 people
- Sponsor
- C4 Therapeutics, Inc.
Multiple Myeloma
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
This study evaluates an individualized approach combining highly active maintenance treatment with elranatamab with peripheral blood-based clonotypic measurable residual disease (MRD) testing in patients with newly diagnosed…
- Trial name
- NCT06483100
- Testing
- Elrantamab, clonoSEQ
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Washington University School of Medicine
Childhood Acute Lymphoblastic Leukemia
NUDT15/TPMT Multi-gene Guided 6-MP Dosing in Childhood ALL Maintenance Therapy
This is a prospective, single-center clinical study to evaluate the safety and efficacy of a personalized 6-mercaptopurine (6-MP) dosing strategy guided by NUDT15 and TPMT genotypes in children with Acute Lymphoblastic Leukemia…
- Trial name
- NCT07462299
- Testing
- NUDT15/TPMT genotype-guided 6-MP dosing
- Where
- China
- Volunteers
- 110 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Recurrent Glioblastoma
Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma
The clinical study of YSCH-01 will adopt an open-label, randomized design, with a planned enrollment of 10 participants with recurrent glioblastoma.
- Trial name
- NCT07538128
- Testing
- YSCH-01, Atezolizumab (1200 mg every three weeks)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Huashan Hospital
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd)…
- Trial name
- Iber-KDd (NCT05896228)
- Testing
- Iberdomide, Carfilzomib, Daratumumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Benjamin T Diamond, MD
Pediatric Cancer, Li-Fraumeni Syndrome
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
This prospective, single-arm, multi-center clinical trial aims to explore and evaluate the efficacy and safety of arsenic trioxide combined with chemotherapy for pediatric cancer with p53 mutation.
- Conditions
- Pediatric Cancer, Li-Fraumeni Syndrome, p53 Mutations
- Trial name
- NCT06088030
- Testing
- Arsenic trioxide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Yang Li
Hypogammaglobulinemia, Bacterial Infections
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in…
- Conditions
- Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma
- Trial name
- EXCELL (NCT05645107)
- Testing
- Xembify
- Where
- 62 sites in United States, Bosnia and Herzegovina and 6 more
- Volunteers
- 386 people
- Sponsor
- Grifols Therapeutics LLC
Pediatric Acute Lymphoblastic Leukemia
Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia
Clinical and genetic factors consistent with High risk : Induction → Consolidation 1. BM MRD \< 0.01% : IM #1 → DI #1 → IM #2 → Maintenance 2. BM MRD ≥ 0.01% : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance 3.
- Trial name
- HR ALL (NCT06184009)
- Testing
- ALL, High risk
- Where
- 9 sites in South Korea
- Volunteers
- 370 people
- Sponsor
- Jae Wook Lee
Non-Hodgkin Lymphoma, Multiple Myeloma
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
The purpose of this study is to determine the uptake of the imaging agent [68Ga]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and…
- Conditions
- Non-Hodgkin Lymphoma, Multiple Myeloma, Histiocytic Neoplasms, Erdheim-Chester Disease
- Trial name
- NCT05093335
- Testing
- [68Ga]-Pentixafor
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastric Cancer (GC), AFP Gastric or Gastroesophageal Junction Adenocarcinoma
Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma
Alpha-fetoprotein-producing gastric cancer (AFP-positive gastric cancer, AFP-GC), a rare and highly aggressive subtype of gastric cancer, accounts for 1.3% to 15% of all gastric cancer cases.
- Trial name
- NCT07515625
- Testing
- Sintilimab, Bevacizumab, Oxaliplatin
- Volunteers
- 46 people
- Sponsor
- Fudan University
Rectal Cancer, Surgery
Safety and Efficacy Study of Single-port Robotic Versus Multi-port Robotic Radical Rectal Cancer Surgery
This study is designed to evaluate the safety and efficacy of single-port robotic surgery compared to multi-port robotic surgery for rectal cancer.
- Trial name
- NCT06943690
- Testing
- Single-port robotic surgery, Multi-port robotic surgery
- Where
- 4 sites in China
- Volunteers
- 212 people
- Sponsor
- Ruijin Hospital
Multiple Sclerosis, Myasthenia Gravis
Serum Auto-Antibodies in Neurological Diseases
Under normal conditions our immune system protects us against infections and tumors. The immune system does this by recognizing that the infecting organism or the tumor is foreign to the body and attacking it.
- Conditions
- Multiple Sclerosis, Myasthenia Gravis, Transverse Myelitis
- Trial name
- SAA (NCT00704626)
- Testing
- Blood Draw, Cheek swab
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of California, Davis
Liver Transplant; Complications, Hepatocarcinoma
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
1. Explore the impact of postoperative administration of multi-kinase inhibitors (including sorafenib, lenvatinib, and regorafenib) in conjunction with bevacizumab on post-transplant recurrence, overall survival, and drug safety…
- Conditions
- Liver Transplant; Complications, Hepatocarcinoma, Recurrent Osteosarcoma, High-Risk Cancer
- Trial name
- NCT06041490
- Testing
- multi-kinase inhibitors in combination with bevacizumab
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Peking Union Medical College Hospital
Refractory Metastatic Colorectal Cancer
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patients with colorectal cancer that has spread to the liver is safe and…
- Trial name
- DEL-LIVER (NCT06607458)
- Testing
- Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil plus Bevacizumab Alone
- Where
- 20 sites in United States, Czechia and 7 more
- Volunteers
- 90 people
- Sponsor
- Delcath Systems Inc.
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Head and Neck Squamous Cell Carcinoma HNSCC
Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial
This study compares two short pre-surgery treatments for locally advanced head and neck squamous cell cancer to see which one keeps the cancer from coming back longer.
- Trial name
- SHINE (NCT07371897)
- Testing
- Docetaxel and Cisplatin, Toripalimab
- Volunteers
- 154 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.